European BioPharmaceutical Review |
 |
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
|
| Maximising press coverage of anything from new product launches, to research, to company restructure is a continuous challenge for biopharmaceutical companies. Michael Willett at Bruker BioSciences outlines the various options available to get your story In the Flow |
|
|
| Robin Ng and Stephanie Finnegan at Goodwin Biotechnology, Inc give their advice on the benefits of attracting high-flying graduates to new roles, and the tactics involved in Winning the War of competitive recruitment within the biopharma industry |
|
|
| Having The Last Word in the press is a key aim for most biopharmaceutical companies. Sue Charles of College Hill examines the value of communications as a key business investment |
|
|
| The up-to-the-minute information, research and opportunity for discussion that the internet can provide has revolutionised the world of scientific communications, argues Sabine Duntze at b3c communications in Weaving a New Web |
|
|
|
| Dr Achim Plum and Dr Oliver Schacht at Epigenomics AG investigate the lucrative potential of companies working together on drug development, and suggest that effective partnering allows even the smallest biotechs to have a chance at Playing in the Big Leagues |
|
|
| One way to get ahead of the biopharma game is through exploiting the full potential of networking within the industry; Dr Kate Rowley at Nexxus, the West of Scotland Bioscience Network, outlines its role in Partnering: the Modern Day Paradigm for Progression |
|
|
| The challenge of transcending national borders is one that most biopharmaceutical companies face at some stage during the drug development process. Dan Zabrowski at Roche persuades that Pursuing Partnerships is the recipe for pioneering progression |
|
|
| Martin Dittmer at Rockwell Automation considers The Path to Paperless Production, and concludes that electronic batch recording can transform every aspect of pharmaceutical manufacturing – from innovation to the marketplace |
|
|
|
| New therapeutic paradigms rarely cause a stir comparable to that of RNAi – everyone from the new generation of biotech entrepreneurs to Wall Street has taken notice, even before its first market approval. Drug development consultant Emile Bellott investigates whether or not this excitement is justified, in A Glass Half-Full |
|
|
| Andreas Busjahn at HealthTwiSt predicts a potentially crucial development for biopharmaceutical R&D in Double Take, asserting that the application of molecular genetics may give the fast-diminishing use of twin studies a second wind |
|
|
| Advances in nanotechnology have opened up the possibility of a new era of personalised oncology, thereby providing cancer patients with more accurate diagnoses and more effective treatment. In This Time it’s Personal, Sylvia M Findlay at Frost & Sullivan assesses the communication difficulties facing this fresh approach |
|
|
|
| With an ever-increasing demand for adapted proteins, taking a synthesised approach could be the answer. Michael Liss and Ralf Wagner at GENEART examine the potential of Tailor-Made Proteins |
|
|
| RNA purification has always been a struggle for low-throughput laboratories due to the lack of automated platforms. In Technological Expression, Carola Shade at QIAGEN GmbH inspects a selection of brand new, innovative methods that can help to streamline the process |
|
|
| In Increasing 15d-PGJ2: a Novel Drug Target, Professor Ernst Wülfert at Hunter-Fleming Ltd believes the production of 15d-PGJ2 should be increased as it boasts several unique properties, despite not currently being a primary target for drug discovery and development |
|
|
| Consistent progress is being made in the development of sensitive and efficient assays to swiftly measure the binding of compounds. In Right on Target, Marion de Decker at Cisbio explores recent advances in what is a key element of the drug discovery process |
|
|
|
| Testing is one of the most costly and time-consuming aspects of a drug’s development cycle, but arguably also the most important. In Minimising Immunological Risk, Markus Wulf and Peter Trinder of Thymed GmbH evaluate the crucial parameters in the clinical and preclinical development process of vaccines, drugs and biotherapeutics |
|
|
| Inhalation toxicology is establishing its predominance as a method for administering an increasing range of therapies, yet the risks involved cannot be ignored and continuous development is imperative in testing systems and protocols. Paul Smith and Richard Crowley at Covance provide us with A Dose of Inspiration |
|
|
| In Making Your Mark, independent consultant Ray Briggs and John Allinson at Veeda Clinical Research attempt to clear up how conflicting definitions of biomarkers, together with discrepancy between the technologies available, have augmented misunderstandings in the past |
|
|
|
|
|
